CXCR3 and proteosome-associated autoinflammatory syndrome: Blockade of the CXCR3 pathway ameliorated the inflammatory responses caused by immunoproteasome dysfunction, suggesting that the CXCR3 pathway could be a drug target in patients with PRAAS.